Home » Stocks » RPTX

Repare Therapeutics, Inc. (RPTX)

Stock Price: $32.26 USD -1.42 (-4.22%)
Updated Apr 19, 2021 2:30 PM EDT - Market open
Market Cap 1.25B
Revenue (ttm) 135,000
Net Income (ttm) -53.42M
Shares Out 36.98M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $32.26
Previous Close $33.68
Change ($) -1.42
Change (%) -4.22%
Day's Open 33.81
Day's Range 32.00 - 33.87
Day's Volume 98,607
52-Week Range 21.45 - 46.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary ...

6 days ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

1 week ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

2 weeks ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

2 weeks ago - Business Wire

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $RPTX #AI--Valence Discovery, an emerging leader in AI-enabled drug design, announced it has entered into a drug discovery agreement with Repare Therapeu...

1 month ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

1 month ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

1 month ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthet...

3 months ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary ...

3 months ago - Business Wire

Synthetic Lethality (SL) is a promising approach for cancer treatments. Repare's SNIPRx platform has the potential to identify SL pairs to create new therapies.

3 months ago - Seeking Alpha

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthet...

4 months ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

4 months ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary syntheti...

5 months ago - Business Wire

Repare Therapeutics (RPTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

7 months ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

8 months ago - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

8 months ago - Business Wire

Repare Therapeutics Inc. (NASDAQ: RPTX), which is working to develop precision oncology therapies by leveraging synthetic lethal interactions in cancer, went public in June.

9 months ago - Benzinga

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RNA, XBI ...
9 months ago - CNN Business

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and d...

9 months ago - Business Wire

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

Other stocks mentioned: FMTX
9 months ago - GuruFocus

About RPTX

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also deve... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is 45.83, which is an increase of 42.06% from the latest price.

Price Target
$45.83
(42.06% upside)
Analyst Consensus: Buy